a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
JGVRX | 29.76 | 0.01 | +0.03% |
JPMorgan Growth Advantage R5 | |||
LSSNX | 25.06 | -0.04 | -0.16% |
Loomis Sayles Small Cap Growth N | |||
CAMIX | 23.11 | -0.06 | -0.26% |
Cambiar International Equity Inv | |||
GFVSX | 13.05 | -0.06 | -0.46% |
Goldman Sachs Focused Value Instl | |||
CGRYX | 33.01 | -0.21 | -0.63% |
Invesco Comstock Select Y |
A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with FATE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then FATE could also see price increases.
Ticker / NAME | Correlation To IMTX | 1D Price Change % | ||
---|---|---|---|---|
IMTX | 100% | -1.18% | ||
FATE - IMTX | 41% Loosely correlated | -3.65% | ||
CYTK - IMTX | 36% Loosely correlated | -0.93% | ||
KNSA - IMTX | 35% Loosely correlated | -2.92% | ||
AUTL - IMTX | 31% Poorly correlated | -12.36% | ||
SNPX - IMTX | 31% Poorly correlated | +30.17% | ||
More |